Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 132.4% in January

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 92,500 shares, a growth of 132.4% from the January 15th total of 39,800 shares. Based on an average trading volume of 497,000 shares, the short-interest ratio is currently 0.2 days.

Astellas Pharma Stock Performance

Shares of ALPMY stock opened at $9.73 on Friday. The stock’s 50-day moving average is $9.71 and its two-hundred day moving average is $10.90. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.86 and a current ratio of 1.10. Astellas Pharma has a 1 year low of $9.05 and a 1 year high of $13.14. The firm has a market cap of $17.61 billion, a price-to-earnings ratio of -44.23 and a beta of 0.34.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share (EPS) for the quarter. Astellas Pharma had a positive return on equity of 13.48% and a negative net margin of 3.10%. Analysts predict that Astellas Pharma will post 0.58 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.